The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients

Leukemia

Volumn 28, Issue 2, 2014, Pages 451-455

  Boysen, J ^a   Sinha, S ^a   Price Troska, T ^a   Warner, S L ^b   Bearss, D J ^b   Viswanatha, D ^a   Shanafelt, T D ^a   Kay, N E ^a   Ghosh, A K ^a  

^a MAYO CLINIC   (United States)

^b Tolero Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXL PROTEIN; DOXORUBICIN; FLUDARABINE; MICRORNA 34A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; B LYMPHOCYTE; BINDING SITE; CANCER PATIENT; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPORTER GENE; UPREGULATION;

3' UNTRANSLATED REGIONS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893767856     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.298     Document Type: Letter

References (15)

1. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011; 117: 1928-1937.
2. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-199.
3. Ghosh AK, Boysen J, Price-troska T, Secreto C, Zent CS, Kay N. Axl receptor tyrosine kinase signaling pathway and the p53 tumor suppressor protein exist in a novel regulatory loop in B-cell chronic lymphocytic leukemia cells. ASH Annu Meet Abstr 2011; 118: 799.
4. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011; 30: 2888-2899.
5. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 2011; 130: 663-679.
6. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D et al. MiR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801-3808.
7. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589-2597.
8. Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB et al. 17P13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 2009; 23: 625-627.
9. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 6521-6532.
10. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999; 13: 152-157.
11. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010; 31: 745-750.
12. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
13. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752.
14. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007; 21: 1885-1891.
15. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 2008; 28: 161-176.